Quantcast

Latest Oxaliplatin Stories

2009-11-17 11:52:00

SOUTH SAN FRANCISCO, Calif., Nov. 17 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD) today announced updated clinical data from its randomized, controlled Phase 2 trial of picoplatin in patients with metastatic colorectal cancer (CRC). The updated results indicated that picoplatin, given once every four weeks in combination with 5-fluorouracil and leucovorin in the FOLPI regimen, has comparable efficacy to oxaliplatin, given in combination with 5-fluorouracil and...

2009-11-05 07:03:00

THOUSAND OAKS, Calif., Nov. 5 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) today announced that the Phase 3 PRIME "203" trial evaluating Vectibix® (panitumumab) administered in combination with FOLFOX (an oxaliplatin-based chemotherapy) as a first-line treatment of metastatic colorectal cancer (mCRC) failed to meet a secondary endpoint of overall survival. Earlier this year, it was announced that the trial met its primary endpoint by significantly prolonging...

2009-11-03 09:58:00

NEW YORK, Nov. 3 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue. Chinese Markets for Colon Cancer Treatment Drugs http://www.reportlinker.com/p0157398/Chinese-Markets-for-Colon-Cancer-Treatment-Drugs.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=prnewswire China's demand for Colon Cancer Treatment Drugs has grown at a fast pace in the past decade. In the next five years, both production and demand will continue...

2009-10-26 14:36:00

DURHAM, N.C., Oct. 26 /PRNewswire/ -- In a review article published this month in The Oncologist, UNC's Dr. Richard M. Goldberg and a team of colleagues catalogue how the data collected in a single large comparative clinical trial testing combination chemotherapy for metastatic colorectal cancer has been used not only to benefit the patients that enrolled but also patients who subsequently developed the disease. (Logo: http://www.newscom.com/cgi-bin/prnh/20080627/CLF051LOGO ) It has also...

2009-09-24 02:37:00

THOUSAND OAKS, Calif., Sept. 24 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) today announced detailed results from the Phase 3 '203' trial evaluating Vectibix(R) (panitumumab) administered in combination with FOLFOX (an oxaliplatin-based chemotherapy) as the first-line treatment of metastatic colorectal cancer (mCRC). In this trial, Vectibix significantly improved median progression-free survival (PFS) by 1.6 months (9.6 versus 8.0 months for patients treated with FOLFOX alone, (hazard...

2009-08-21 10:06:07

Colorectal cancer (CRC) is the second leading cause of cancer-related death in the Western world. Fortunately physicians today have an abundance of drug therapies available to improve survival length for more advanced cancer patients. Now the discovery of genetic biomarkers relevant to CRC means that targeted personalized medication is increasingly common.CRC affects approximately 150,000 patients and leads to over 52,000 deaths every year in the US alone. In the early stages, CRC can often...

2009-08-11 10:29:00

LAKE FOREST, Ill., Aug. 11 /PRNewswire-FirstCall/ -- Hospira, Inc. (NYSE: HSP), the world leader in generic injectable pharmaceuticals, today announced U.S. Food and Drug Administration (FDA) approval and launch of oxaliplatin injection in the United States. The medication is a generic version of Sanofi-Aventis' Eloxatin(R), which posted 2008 U.S. sales of approximately $1.4 billion. Hospira's oxaliplatin injection is one of the first generic versions of this drug to come in solution form....

2009-08-06 15:03:00

THOUSAND OAKS, Calif., Aug. 6 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) today announced that Vectibix((R)) (panitumumab), administered in combination with FOLFOX (an oxaliplatin-based chemotherapy), significantly prolonged progression-free survival (PFS) compared with FOLFOX alone in the first-line treatment of patients with KRAS wild-type metastatic colorectal cancer (mCRC). "We believe that these data document an important advance for patients with metastatic colorectal cancer,"...

2009-08-05 07:00:00

BETHESDA, Md. and BRIDGEWATER, N.J., Aug. 5 /PRNewswire-FirstCall/ -- Today, the Foundation for the National Institutes of Health and sanofi-aventis announced an unprecedented donation by the global pharmaceutical leader providing approximately $1.3 million in pharmaceutical therapies for ongoing use in clinical trials and other therapeutic treatments at the National Institutes of Health (NIH) Clinical Center. Designated by the Foundation for NIH as the Clinical Center Drug Donation...

2009-07-17 18:10:00

THOUSAND OAKS, Calif., July 17 /PRNewswire-FirstCall/ -- Amgen Inc. (Nasdaq: AMGN) today announced the U.S. Food and Drug Administration (FDA) has approved revisions to the U.S. prescribing information for the epidermal growth factor receptor (EGFr) class of antibodies, including Vectibix((R)) (panitumumab). This decision follows the FDA's December 2008 Oncologics Drugs Advisory Committee (ODAC) meeting where the clinical utility of the KRAS gene as a predictive biomarker in patients with...


Word of the Day
cruet
  • A vial or small glass bottle, especially one for holding vinegar, oil, etc.; a caster for liquids.
This word is Middle English in origin, and ultimately comes from the Old French, diminutive of 'crue,' flask.
Related